Active substances
Piperacillin + Tazobactam
- SFDA 11
- US FDA 25
- Health Canada 16
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| PIPERACILLIN - TAZOPACTAM SANDOZ 2.25GM VIAL | 2,0.25 g,g | Powder for solution for infusion · Intravenous use | 1 Vial | SAR 23.25 | Generic · Prescription | SANDOZ | Valid |
| PIPERACILLIN - TAZOPACTAM SANDOZ 4.5GM VIAL | 4,0.5 g,g | Powder for solution for infusion · Intravenous use | 10 Vial | SAR 550.55 | Generic · Prescription | SANDOZ | Valid |
| PRIZMA 2GM/0.25GM POWDER FOR I.V. INFUSION | 2,0.25 g,g | Powder for solution for infusion · Intravenous use | 1 Vial | SAR 35.60 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| PRIZMA 4GM-0.5GM POWDER FOR I.V INFUSION | 4,0.5 g,g | Powder for solution for infusion · Intravenous use | 1 Vial | SAR 71.25 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Pipractam | 4.5 g | Lyophilisate for solution for infusion · Intravenous use | 10 Vial | SAR 562.65 | Generic · Prescription | SAUDI DOX FOR PHARMACEUTICAL INDUSTRIES | Valid |
| Pipractam | 2.25 g | Lyophilisate for solution for infusion · Intravenous use | 10 Vial | SAR 299.45 | Generic · Prescription | SAUDI DOX FOR PHARMACEUTICAL INDUSTRIES | Valid |
| TAZOCIN 4.5GM VIAL + EDTA | 4,0.5 g,g | Powder for solution for infusion · Intravenous use | 1 Vial | SAR 92.85 | Generic · Prescription | WYETH | Valid |
| TAZORAX 2.25 GM Powder for injection | 2,0.25 g,g | powder for solution for injection · Intravenous use | 1 Vial | SAR 32.05 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| TAZORAX 4.5 GM Powder for injection | 4,0.5 g,g | powder for solution for injection · Intravenous use | 1 Vial | SAR 64.10 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| PIPERACILLIN - TAZOPACTAM SANDOZ 4.5GM VIAL | 4,0.5 g,g | Powder for solution for infusion · Intravenous use | 1 Vial | SAR 46.55 | Generic · Prescription | SANDOZ | Withdrawn by MAH · Not Marketed |
| TAZOCIN 2.25G VIAL | 2000, 250 mg | Solution · Intravenous use | 1 Vial | SAR 29.05 | NCE · Prescription | LEDERLE | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE BACTERIAL PROSTATITIS; ACUTE EXACERBATION OF BRONCHIECTASIS (NON-CYSTIC FIBROSIS); ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD); ACUTE PANCREATITIS; ACUTE PYELONEPHRITIS; ANTIBIOTIC SURGICAL PROPHYLAXIS; BACTERIAL SKIN INFECTIONS - ERYSIPELAS AND CELLULITIS; BACTERIAL SKIN INFECTIONS - GAS GANGRENE; BACTERIAL SKIN INFECTIONS - NECROTIZING FASCIITIS; BACTERIAL SKIN INFECTIONS - SURGICAL SITE INFECTIONS; COMMUNITY ACQUIRED PNEUMONEA; DENTAL ABSCESS; HOSPITAL AND VENTILATER ACQUIRED PNEUMONIA; INTRA-ABDOMINAL INFECTIONS; OSTEOMYELITIS; PERITONITIS; Pyogenic Arthritis; RECURRENT URINARY TRACT INFECTIONS (UTI); Septic Shock
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ZOSYN IN PLASTIC CONTAINER | EQ 40MG BASE/ML;EQ 5MG BASE/ML; EQ 60MG BASE/ML;EQ 7.5MG BASE/ML; EQ 4GM BASE/100ML;EQ 500MG BASE/100ML | injectable · injection | BAXTER HLTHCARE CORP | Prescription | 24 Feb 1998 |
| PIPERACILLIN AND TAZOBACTAM | EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL; EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL; EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL | injectable · injection | SANDOZ | Prescription | 21 Oct 2010 |
| PIPERACILLIN AND TAZOBACTAM | EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL; EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL; EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL | injectable · injection | EUGIA PHARMA SPECLTS | Prescription | 23 May 2011 |
| PIPERACILLIN AND TAZOBACTAM | EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL; EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL; EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL | injectable · injection | ACS DOBFAR SPA | Prescription | 31 May 2011 |
| PIPERACILLIN AND TAZOBACTAM | EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL | injectable · injection | ACS DOBFAR SPA | Prescription | 31 May 2011 |
| PIPERACILLIN AND TAZOBACTAM | EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL; EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL; EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL | injectable · injection | ONESOURCE SPECIALTY | Prescription | 15 Aug 2014 |
| PIPERACILLIN AND TAZOBACTAM | EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL; EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL | injectable · injection | SANDOZ | Prescription | 29 Oct 2014 |
| PIPERACILLIN AND TAZOBACTAM | EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL; EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL; EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL | injectable · injection | MILLA PHARMS | Prescription | 13 Jan 2017 |
| PIPERACILLIN AND TAZOBACTAM | EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL; EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL | injectable · injection | MILLA PHARMS | Prescription | 13 Jan 2017 |
| PIPERACILLIN AND TAZOBACTAM | EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL | injectable · injection | APOTEX | Prescription | 17 Mar 2017 |
| PIPERACILLIN AND TAZOBACTAM | EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL; EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL; EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL | injectable · injection | APOTEX | Prescription | 22 Mar 2017 |
| PIPERACILLIN AND TAZOBACTAM | EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL | injectable · injection | FRESENIUS KABI | Prescription | 11 May 2018 |
| PIPERACILLIN AND TAZOBACTAM | EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL; EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL; EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL | injectable · injection | FRESENIUS KABI | Prescription | 18 May 2018 |
| PIPERACILLIN AND TAZOBACTAM | EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL; EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL; EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL | injectable · injection | SHANDONG | Prescription | 10 Aug 2018 |
| PIPERACILLIN AND TAZOBACTAM | EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL; EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL; EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL | injectable · injection | SAGENT PHARMS INC | Prescription | 16 Feb 2021 |
| PIPERACILLIN AND TAZOBACTAM | EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL | injectable · injection | SAGENT PHARMS INC | Prescription | 16 Feb 2021 |
| PIPERACILLIN AND TAZOBACTAM | EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL | injectable · injection | SHANDONG | Prescription | 14 Apr 2023 |
| PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER | EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL; EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL; EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL | powder · intravenous | B BRAUN MEDICAL | Prescription | 3 Apr 2025 |
| ZOSYN | EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | WYETH PHARMS | Discontinued | 22 Oct 1993 |
| PIPERACILLIN AND TAZOBACTAM | EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL; EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL; EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL | injectable · injection | HOSPIRA INC | Discontinued | 15 Sep 2009 |
| PIPERACILLIN AND TAZOBACTAM | EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL | injectable · injection | HOSPIRA INC | Discontinued | 15 Sep 2009 |
| PIPERACILLIN AND TAZOBACTAM | EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL; EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL; EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL | injectable · injection | SANDOZ | Discontinued | 21 Oct 2010 |
| PIPERACILLIN AND TAZOBACTAM | EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL | injectable · injection | FRESENIUS KABI USA | Discontinued | 11 May 2018 |
| PIPERACILLIN AND TAZOBACTAM | EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL; EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL; EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL | injectable · injection | ASTRAL | Discontinued | 29 Jul 2019 |
| PIPERACILLIN AND TAZOBACTAM | EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL; EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL | injectable · injection | EUGIA PHARMA | Discontinued | 12 Oct 2023 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 02299623 | 2 G / VIAL; 0.25 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 02299631 | 3 G / VIAL; 0.375 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 02299658 | 4 G / VIAL; 0.5 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 02330547 | 1.5 G / VIAL; 12 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 02362619 | 2.00 G / VIAL; 0.25 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | STERIMAX INC |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 02362627 | 3.000 G / VIAL; 0.375 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | STERIMAX INC |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 02362635 | 0.5 G / VIAL; 4.0 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | STERIMAX INC |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 02377748 | 1.5 G / VIAL; 12 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | STERIMAX INC |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 02402068 | 2 G / VIAL; 0.25 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | AURO PHARMA INC |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 02402076 | 0.375 G / VIAL; 3 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | AURO PHARMA INC |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 02402084 | 4 G / VIAL; 0.5 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | AURO PHARMA INC |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 02439131 | 36 G / VIAL; 4.5 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | STERIMAX INC |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 02521539 | 4.5 G / VIAL; 36 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 02528673 | 2 G / VIAL; 0.25 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | EUGIA PHARMA INC. |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 02528703 | 0.375 G / VIAL; 3 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | EUGIA PHARMA INC. |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 02528711 | 0.5 G / VIAL; 4 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | EUGIA PHARMA INC. |
WHO WHO Model List of Essential Medicines (2025)
- 6.2.2. Watch group antibiotics · core
First choice: Other specified pneumonia (Hospital-acquired pneumonia); First choice: Neutropaenia (high-risk); First choice: Peritoneal abscess (severe); First choice: Peritonitis (severe); First choice: Necrotising fasciitis (co-prescribed with clindamycin)
Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.